Business
Theralase Launches Anti-Cancer Therapy Research Centre
TORONTO, ON / ACCESSWIRE / March 29, 2021 / Theralase® Technologies Inc. (" Theralase "...
About this update from Theralase Technologies Inc.
[{"type":"text","content":"Theralase Launches Anti-Cancer Therapy Research CentreTORONTO, ON / ACCESSWIRE / March 29, 2021 / Theralase® Technologies Inc. (\"Theralase\" or the \"Company\") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (\"PDC\") and their associated drug formulations used to safely and effectively destroy various cancers, bacteria and viruses announced today the launch of the Theralase® Anti-Cancer Therapy (\"ACT\") research centre located within the Li Ka Shing Knowledge Institute of St. Michael's Hospital, Unity Health Toronto, effective April 1, 2022, relocating its research team from University Health Network (\"UHN\"), Toronto.The Li Ka Shing Knowledge Institute of St. Michael's is home to leading researchers, educators and clinicians - dedicated professionals making new scientific discoveries, generating novel therapies, developing innovative training programs and helping translate knowledge into practice.The ACT research centre is a fully equipped laboratory dedicated exclusively to Theralase® ACT research and development as it advances towards commercialization with its lead PDC, TLD-1433, as well as its systemic and targeted formulation - Rutherrin®. A Partnership with the Li Ka Shing Knowledge Institute of Unity Health provides access to additional expertise, advisory networks and opportunities to accelerate product development and commercialization.Dr. Ori Rotstein MD, Msc., Vice President of Research and Innovation at Unity Health, Professor and Associate Chair of the Department of Surgery at University of Toronto welcomed Theralase® stating, \"Our research facilities uniquely align scientific, clinical and business initiatives, which helps to accelerate our partners' path to market by validating their solutions directly in the healthcare setting starting at the research bench and culminating to clinical studies.\"Michael Jewett MD, FRCSC, FACS, CM, Departments of Surgery (Urology), University of Toronto and Chair, Theralase Medical and Scientific Advisory Board, stated \"I am delighted by the research and clinical milestones that the Theralase® team has been able to achieve in advancing its PDC technology, including, launching a Phase II Non-Muscle Invasive Bladder Cancer (\"NMIBC\") pivotal clini...